Photobiomodulation: The Science Behind Red Light

Photobiomodulation (PBM) is the scientific term for what most people know as “red light therapy” or “low-level laser therapy.” It describes the process by which non-ionising light — typically in the red (600–700nm) and near-infrared (760–1000nm) spectrum — produces biological effects in living tissue without heating it.

Understanding PBM is essential for anyone evaluating red light therapy claims. It separates evidence-based applications from marketing hype, explains why certain wavelengths and doses work whilst others do not, and provides the framework for interpreting clinical research. This article covers the full science: history, mechanism, key researchers, dose response, clinical acceptance, and how PBM differs from other light-based therapies.

A Brief History of the Term

The story of PBM begins with a laser and a shaved mouse.

From Laser Biostimulation to LLLT

In 1967, Hungarian physician Endre Mester conducted what is widely regarded as the first PBM experiment. Attempting to replicate reports that laser light could destroy tumours, Mester shaved mice and irradiated them with a low-power 694nm ruby laser. The laser was too weak to affect the tumours, but Mester noticed something unexpected: the shaved hair grew back faster in the irradiated mice than in the controls (Mester et al., 1968).

This observation launched the field of “laser biostimulation.” Over the following decades, the terminology shifted to “low-level laser therapy” (LLLT), reflecting the clinical applications being explored — wound healing, pain reduction, inflammation control. The term LLLT dominated the literature from the 1970s through the early 2010s.

The Problem with “LLLT”

By the 2000s, it had become clear that “low-level laser therapy” was a misleading name. Research consistently demonstrated that LEDs (light-emitting diodes) produced the same biological effects as lasers at equivalent wavelengths and power densities. The therapeutic mechanism did not require coherent light — it required photons at the right wavelength, delivered at the right dose (Whelan et al., 2001; PMID: 11776448).

The “low-level” part was also problematic. It implied that the therapy was defined by being weak, rather than by operating through a specific biological mechanism. And it told clinicians nothing about the actual process occurring in the tissue.

Adoption of “Photobiomodulation”

In 2014, the North American Association for Photobiomodulation Therapy (NAALT) and the World Association for Laser Therapy (WALT) jointly endorsed the term “photobiomodulation” to replace LLLT. The term was subsequently added to the Medical Subject Headings (MeSH) database by the US National Library of Medicine in 2016, making it the official indexing term for PubMed searches (Anders et al., 2015; PMID: 25706882).

The term breaks down simply:

• Photo — light
• Bio — life, biological tissue
• Modulation — change, regulation (not just stimulation, since PBM can both stimulate and inhibit depending on dose)

This last point is important. PBM is not “laser biostimulation” because it does not always stimulate — at high doses, it can inhibit cellular activity. The term modulation captures this biphasic nature.

The Core Mechanism: Cytochrome C Oxidase

The Chromophore

Every light-based therapy requires a chromophore — a molecule that absorbs specific wavelengths of light. In PBM, the primary chromophore is cytochrome c oxidase (CCO), also known as Complex IV of the mitochondrial electron transport chain (Karu, 2005; PMID: 16007521).

CCO is the terminal enzyme in oxidative phosphorylation, the process by which mitochondria produce ATP (adenosine triphosphate), the cell’s energy currency. It contains two copper centres (CuA and CuB) and two haem groups (haem a and haem a₃) that absorb light at specific wavelengths. The absorption spectrum of CCO shows peaks in two main regions:

• Red light (600–700nm) — absorbed primarily by the oxidised form of CCO
• Near-infrared (760–900nm) — absorbed primarily by the reduced form of CCO

These absorption bands explain why PBM research focuses on red and near-infrared wavelengths. Other visible light colours (blue, green, yellow) do interact with biological tissue, but through different chromophores and mechanisms, and generally with less therapeutic evidence for the deep-tissue effects associated with PBM.

The Nitric Oxide Hypothesis

Under normal conditions, nitric oxide (NO) binds to CCO at the same site where oxygen binds — the haem a₃/CuB binuclear centre. This NO binding inhibits CCO activity, reducing the rate of electron transport and lowering ATP production. In stressed, hypoxic, or inflamed cells, excess NO can significantly impair mitochondrial function (Poyton and Ball, 2011; PMID: 21117902).

When photons at the right wavelength strike CCO, they photodissociate NO from the enzyme. This restores normal oxygen binding, re-establishes electron flow through the transport chain, and increases ATP synthesis. The displaced NO itself becomes a signalling molecule, triggering vasodilation and other downstream effects (Hamblin, 2017; PMID: 28748217).

This is the central mechanism of PBM in a single sentence: light displaces nitric oxide from cytochrome c oxidase, restoring mitochondrial function and increasing ATP production.

Downstream Signalling Cascade

The initial photochemical event — NO displacement from CCO — triggers a cascade of secondary effects:

1. Increased ATP production — Cells have more energy available for repair, proliferation, and protein synthesis.
2. Brief ROS burst — A transient increase in reactive oxygen species (ROS), particularly superoxide, activates redox-sensitive transcription factors such as NF-κB and AP-1. These transcription factors upregulate genes involved in cell survival, proliferation, and anti-inflammatory responses (Chen et al., 2011; PMID: 21182908).
3. Nitric oxide signalling — The photodissociated NO diffuses into surrounding tissue, causing local vasodilation and improving blood flow. This enhances oxygen and nutrient delivery to the treated area.
4. Calcium signalling — PBM has been shown to modulate intracellular calcium levels, which influence numerous cellular processes including muscle contraction, neurotransmitter release, and gene expression (Sharma et al., 2011; PMID: 22166016).
5. Anti-inflammatory effects — PBM reduces pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and increases anti-inflammatory cytokines (IL-10). Multiple pathways contribute, including NF-κB modulation and prostaglandin reduction (Hamblin, 2017; PMID: 28748217).
6. Collagen and growth factor upregulation — In fibroblasts and other connective tissue cells, PBM increases production of collagen types I and III, transforming growth factor-β (TGF-β), fibroblast growth factor (FGF), and vascular endothelial growth factor (VEGF).

The net result is a cell that is producing more energy, experiencing less inflammatory stress, proliferating faster, and synthesising more structural proteins. These effects explain why PBM shows therapeutic potential across such a wide range of conditions — the underlying mechanism is universal to all mitochondria-containing cells.

The Biphasic Dose Response

One of the most important — and most frequently ignored — principles in PBM is the biphasic dose response, also called the Arndt-Schulz curve. This principle states that biological responses to PBM follow an inverted U-shaped curve (Huang et al., 2009; PMID: 19764898):

• Too little light: No measurable biological effect. The threshold has not been reached.
• Optimal dose: Therapeutic benefit. Typically 3–10 J/cm² for surface tissues, potentially higher for deep targets after accounting for tissue attenuation.
• Too much light: Inhibitory or even damaging effects. Excessive ROS production overwhelms antioxidant defences. Cells become stressed rather than stimulated.

This biphasic response has been demonstrated in vitro, in animal models, and in clinical trials. It explains why “more is not better” in PBM and why simply increasing treatment time or power does not guarantee improved outcomes.

The practical implication for consumers: a device delivering 100 mW/cm² is not twice as good as one delivering 50 mW/cm². At higher irradiances, treatment times must be shortened to stay within the optimal dose window. The total energy delivered to the tissue (fluence, measured in J/cm²) is what matters, and exceeding the optimal range produces diminishing or negative returns.

Calculating Dose

The fundamental dosing equation in PBM is:

Fluence (J/cm²) = Irradiance (W/cm²) × Time (seconds)

For a device delivering 50 mW/cm² (0.05 W/cm²):

• 4 J/cm² requires 80 seconds
• 8 J/cm² requires 160 seconds (2 minutes 40 seconds)
• 20 J/cm² requires 400 seconds (6 minutes 40 seconds)

Most clinical studies achieving positive results used fluences between 3 and 10 J/cm² at the tissue surface. Higher doses (above 15–20 J/cm²) have sometimes produced negative results, consistent with the biphasic model.

Key Researchers in PBM

Tiina Karu (1940–2017)

Russian biophysicist Tiina Karu is often called the mother of photobiomodulation. Working at the Institute of Laser and Information Technologies in Moscow, Karu conducted pioneering research identifying CCO as the primary chromophore for red and near-infrared light therapy. Her 1998 book The Science of Low-Power Laser Therapy remains a foundational text (Karu, 1998).

Karu’s action spectra experiments — measuring biological responses at multiple wavelengths and plotting them against the absorption spectrum of CCO — provided the strongest evidence linking PBM effects to mitochondrial absorption. Her work established that the therapeutic effect was photochemical (light absorbed by a specific molecule) rather than photothermal (tissue heating) (Karu, 2005; PMID: 16007521).

Michael R. Hamblin

Michael Hamblin, formerly of Harvard Medical School and Massachusetts General Hospital, has published over 500 papers on photobiomodulation and photodynamic therapy. Hamblin’s research has been instrumental in elucidating the molecular mechanisms of PBM, particularly the role of nitric oxide photodissociation and the downstream signalling cascades.

Hamblin has also been a prominent advocate for expanding PBM research into neurology, demonstrating in animal models and early clinical trials that transcranial PBM may benefit traumatic brain injury, stroke, Alzheimer’s disease, and depression (Hamblin, 2016; PMID: 26535475). His 2018 review “Mechanisms and Mitochondrial Redox Signaling in Photobiomodulation” is one of the most cited papers in the field.

Hoon Chung

Hoon Chung, working with Hamblin at Harvard, contributed seminal work on the biphasic dose response in PBM. Chung’s 2012 review paper (Chung et al., 2012; PMID: 22220949) provided a comprehensive framework for understanding why low doses stimulate and high doses inhibit, with particular attention to the role of ROS in mediating both effects.

Juanita Anders

Juanita Anders of the Uniformed Services University has been a key figure in establishing PBM for neurological applications, particularly traumatic brain injury. Anders led the effort to standardise PBM terminology, chairing the committee that proposed “photobiomodulation” as the replacement for LLLT (Anders et al., 2015; PMID: 25706882).

Harry Whelan

NASA researcher Harry Whelan conducted some of the earliest studies using LED arrays for wound healing, demonstrating that 630nm and 880nm LEDs accelerated tissue repair in both terrestrial and space medicine contexts (Whelan et al., 2001; PMID: 11776448). Whelan’s work was significant because it proved that LEDs — not just lasers — could produce therapeutic PBM effects, opening the door to affordable consumer devices.

How PBM Differs from Photodynamic Therapy

PBM and photodynamic therapy (PDT) both use light on tissue, but they are fundamentally different therapies:

Parameter	Photobiomodulation (PBM)	Photodynamic Therapy (PDT)
Goal	Stimulate or modulate cellular function	Destroy abnormal cells
Photosensitiser	None required — uses endogenous chromophore (CCO)	Requires exogenous photosensitiser (ALA, MAL, porfimer sodium)
Mechanism	Photochemical: NO displacement from CCO → ATP increase	Photochemical: photosensitiser generates singlet oxygen → cell death
Tissue effect	Non-destructive, pro-healing	Destructive, cytotoxic
Typical wavelengths	630–670nm (red), 810–850nm (NIR)	630nm (for PpIX), 652nm (for Photofrin), 730nm (for certain agents)
Clinical use	Pain, wound healing, inflammation, skin rejuvenation	Actinic keratosis, basal cell carcinoma, Barrett’s oesophagus
Regulation	Many devices are consumer-grade; some medical-grade	Medical procedure requiring trained clinician

The confusion arises because both therapies may use similar wavelengths (particularly 630nm). The critical distinction: PDT requires a photosensitising drug to be applied first. Without the photosensitiser, illumination at 630nm produces PBM effects (stimulation), not PDT effects (destruction).

How PBM Differs from Other Light Therapies

UV Phototherapy

Ultraviolet phototherapy (UVA, UVB, narrowband UVB) is used to treat psoriasis, vitiligo, and other skin conditions. UV light operates through entirely different mechanisms — primarily modulating immune cells and DNA synthesis in the skin. It is ionising at shorter UV wavelengths and carries risks of skin damage, photoageing, and carcinogenesis. PBM uses non-ionising red and near-infrared light with no known carcinogenic risk.

Bright Light Therapy

Bright light therapy for seasonal affective disorder (SAD) and circadian rhythm disorders operates through the retinal-hypothalamic pathway, affecting melatonin and cortisol secretion. It uses broad-spectrum white or blue-enriched light and acts on the suprachiasmatic nucleus via retinal ganglion cells. This is a neuroendocrine mechanism entirely separate from PBM’s mitochondrial pathway.

Infrared Saunas

Infrared saunas use far-infrared radiation (typically 3,000–10,000nm) to heat tissue directly. This is a photothermal effect — the health benefits (if any) come from heating the body and inducing sweating, not from photochemical interactions with mitochondria. PBM specifically operates without significant tissue heating.

Current Clinical Acceptance

Where PBM Has Strong Evidence

PBM has reached clinical guideline status for several conditions:

• Oral mucositis in cancer patients — The Multinational Association of Supportive Care in Cancer (MASCC/ISOO) recommends PBM for prevention of oral mucositis in patients receiving certain chemotherapy and radiotherapy regimens (Zadik et al., 2019; PMID: 31286154). This is the strongest clinical endorsement PBM has received from a mainstream medical organisation.
• Musculoskeletal pain — WALT has published dosing guidelines for tendinopathy, osteoarthritis, and myofascial pain based on systematic reviews of randomised controlled trials. Meta-analyses by Bjordal et al. (2003; PMID: 12580742) and Chow et al. (2009; PMID: 19913903) have found statistically significant pain reduction with LLLT/PBM.
• Wound healing — The evidence for accelerated wound healing spans decades, from Mester’s original mouse experiments to modern RCTs in diabetic ulcers and surgical wounds. A Cochrane-style review by Woodruff et al. (2004; PMID: 15117489) found positive effects on wound healing with appropriate dosing parameters.
• Androgenetic alopecia — Multiple FDA-cleared devices use PBM (primarily at 650nm) for hair growth, based on sham-controlled RCTs showing significant increases in hair density.

Where Evidence Is Emerging

Active research areas with promising but not yet definitive evidence include:

• Traumatic brain injury — Naeser et al. (2014; PMID: 24568233) published case series showing improved cognitive function following transcranial PBM in TBI patients. Randomised trials are ongoing.
• Major depressive disorder — Cassano et al. (2016; PMID: 26989758) conducted a pilot study of transcranial PBM for depression with promising results. Larger trials are needed.
• Alzheimer’s disease — Saltmarche et al. (2017; PMID: 28211344) reported case series improvements in cognition with transcranial and intranasal PBM. Early-stage evidence only.
• Age-related macular degeneration — Preliminary studies suggest PBM may improve visual acuity in early AMD, though large RCTs are still required (Markowitz et al., 2020; PMID: 31674920).

Where Scepticism Is Warranted

Some claimed applications of PBM have weak or no supporting evidence:

• Weight loss and body contouring (low-quality evidence, plausible but unproven)
• Testosterone enhancement (very limited data, mostly from animal models)
• Athletic performance enhancement (mixed results, methodological issues in many studies)
• Cancer treatment (PBM is not a cancer treatment; it is used supportively for treatment side effects)

Professional Organisations

WALT — World Association for Laser Therapy

Founded in 1994, WALT is the primary international scientific organisation for PBM research. WALT publishes dosing guidelines, organises biennial congresses, and maintains treatment recommendations based on systematic evidence review. WALT guidelines are widely referenced in PBM research papers and are considered the closest thing to an international standard for PBM treatment parameters.

NAALT — North American Association for Photobiomodulation Therapy

NAALT focuses on education, research advocacy, and regulatory engagement in North America. NAALT was instrumental in the adoption of the “photobiomodulation” terminology and works to promote evidence-based clinical adoption of PBM. The organisation collaborates with WALT on international consensus statements.

ASBrPBM — Brazilian Association for Photobiomodulation

Brazil has been a major contributor to PBM research, particularly in dentistry and wound healing. The Brazilian Association for Photobiomodulation promotes research standards and clinical education within Latin America.

Common Misconceptions

”You need a laser, not LEDs”

This was debated in the early 2000s and is now settled. Multiple studies have demonstrated equivalent biological effects from lasers and LEDs at the same wavelength and power density (Whelan et al., 2001; PMID: 11776448; Chaves et al., 2014; PMID: 24981890). Coherence and collimation — properties unique to lasers — do not contribute to the PBM mechanism at the cellular level. What matters is wavelength, irradiance, and dose.

”Red light therapy is just a heat lamp”

PBM operates through a photochemical mechanism, not a photothermal one. The light energies used in PBM do not significantly raise tissue temperature. Studies have verified therapeutic effects at irradiances far too low to cause any measurable heating (Karu, 2005; PMID: 16007521). If your device makes your skin noticeably hot, you are likely exceeding optimal PBM parameters and entering thermal territory.

”More power is always better”

The biphasic dose response directly contradicts this claim. Clinical evidence repeatedly shows that moderate doses outperform high doses, and that excessive irradiation can inhibit rather than stimulate biological processes. The optimal dose window is relatively narrow, and respecting it is more important than maximising power output (Huang et al., 2009; PMID: 19764898).

”PBM works through the placebo effect”

Sham-controlled trials using inactive (non-emitting) devices as placebos have consistently shown statistically significant effects in the active treatment groups. The MASCC/ISOO oral mucositis guidelines are based on randomised, sham-controlled trials. Whilst placebo effects exist in any therapy, the cellular and molecular changes induced by PBM have been measured objectively in vitro (where there is no placebo) and in animal models.

The State of PBM in 2026

PBM is at an interesting inflection point. The underlying science is well-established: the CCO mechanism, the biphasic dose response, and the downstream signalling pathways are supported by thousands of in vitro, animal, and clinical studies. Several clinical applications have reached guideline-level evidence.

Yet mainstream medical adoption remains limited. Most physicians do not learn about PBM in medical school. Insurance coverage is rare outside of specific dental and wound-care applications. And the consumer market is flooded with devices making unsubstantiated claims, which undermines the credibility of the legitimate science.

For consumers, the key takeaway is that PBM is real biology — not pseudoscience, not placebo, and not marketing. But it is also not a miracle cure. It works through a specific, well-characterised mechanism, at specific wavelengths and doses, for specific conditions with varying levels of evidence. Understanding these boundaries is what separates informed use from wishful thinking.

References

1. Mester E, et al. Effect of laser on hair growth of mice. Kiserl Orvostud. 1968;19:628-631.
2. Whelan HT, et al. Effect of NASA light-emitting diode irradiation on wound healing. J Clin Laser Med Surg. 2001;19(6):305-314. PMID: 11776448
3. Anders JJ, et al. Low-level light/laser therapy versus photobiomodulation therapy. Photomed Laser Surg. 2015;33(4):183-184. PMID: 25706882
4. Karu TI. Multiple roles of cytochrome c oxidase in mammalian cells under action of red and IR-A radiation. IUBMB Life. 2005;57(8):607-615. PMID: 16007521
5. Karu TI. The Science of Low-Power Laser Therapy. Gordon and Breach; 1998.
6. Poyton RO, Ball KA. Therapeutic photobiomodulation: nitric oxide and a novel function of mitochondrial cytochrome c oxidase. Discov Med. 2011;11(57):154-159. PMID: 21117902
7. Hamblin MR. Mechanisms and applications of the anti-inflammatory effects of photobiomodulation. AIMS Biophys. 2017;4(3):337-361. PMID: 28748217
8. Chen AC, et al. Low-level laser therapy activates NF-kB via generation of reactive oxygen species in mouse embryonic fibroblasts. PLoS One. 2011;6(7):e22453. PMID: 21182908
9. Sharma SK, et al. Dose response effects of 810 nm laser light on mouse primary cortical neurons. Lasers Surg Med. 2011;43(8):851-859. PMID: 22166016
10. Huang YY, et al. Biphasic dose response in low level light therapy. Dose Response. 2009;7(4):358-383. PMID: 19764898
11. Chung H, et al. The nuts and bolts of low-level laser (light) therapy. Ann Biomed Eng. 2012;40(2):516-533. PMID: 22220949
12. Hamblin MR. Shining light on the head: photobiomodulation for brain disorders. BBA Clin. 2016;6:113-124. PMID: 26535475
13. Zadik Y, et al. Systematic review of photobiomodulation for the management of oral mucositis. Support Care Cancer. 2019;27(10):3621-3629. PMID: 31286154
14. Bjordal JM, et al. A systematic review of low level laser therapy with location-specific doses for pain from chronic joint disorders. Aust J Physiother. 2003;49(2):107-116. PMID: 12580742
15. Chow RT, et al. Efficacy of low-level laser therapy in the management of neck pain: a systematic review and meta-analysis. Lancet. 2009;374(9705):1897-1908. PMID: 19913903
16. Woodruff LD, et al. The efficacy of laser therapy in wound repair: a meta-analysis of the literature. Photomed Laser Surg. 2004;22(3):241-247. PMID: 15117489
17. Naeser MA, et al. Significant improvements in cognitive performance post-transcranial, red/near-infrared light-emitting diode treatments in chronic, mild traumatic brain injury. Arch Clin Neuropsychol. 2014;29(2):152-162. PMID: 24568233
18. Cassano P, et al. Review of transcranial photobiomodulation for major depressive disorder: targeting brain metabolism, inflammation, oxidative stress, and neurogenesis. Neurophotonics. 2016;3(3):031404. PMID: 26989758
19. Saltmarche AE, et al. Significant improvement in cognition in patients with dementia: transcranial plus intranasal photobiomodulation. Alzheimers Dement (N Y). 2017;3(3):348-353. PMID: 28211344
20. Markowitz SN, et al. A double-masked, randomized, sham-controlled, single-centre study with photobiomodulation for the treatment of dry age-related macular degeneration. Retina. 2020;40(8):1471-1482. PMID: 31674920
21. Chaves ME, et al. Effects of low-power light therapy on wound healing: LASER x LED. An Bras Dermatol. 2014;89(4):616-623. PMID: 24981890